Manila Times Business
WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations
SHANGHAI, June 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance facility located at the Shanghai Fengxian site has successfully completed its first GMP production campaign. The manufacturing process execution was completed with zero deviations, while critical process parameters remained stable and yields reached expected levels, demonstrating robust process performanc
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Trump orders probe because gas prices not falling enough
5h ago
HKPC Leads Four Hong Kong I&T Enterprises to Paris VivaTech 2026 Leveraging Hong Kong's "Two-Way Springboard" Strategic Advantage to Accelerate Global Markets Connections
5h ago
ATLANT 3D, A*STAR IMRE and NAMIC Sign MoU to Advance AI-Driven Materials Discovery in Singapore
5h ago
TECNO Showcases Expanded EllaClaw Capabilities, Advancing Practical Agentic AI that Gets Things Done
5h ago